PCSK9 (laroprovstat component) + HMG-CoA reductase

Class

Fixed-dose combination: oral small-molecule PCSK9 inhibitor + statin (HMG-CoA reductase inhibitor)

Pathway

Laroprovstat (AZD0780) is an oral small-molecule PCSK9 inhibitor blocking PCSK9-mediated LDL-receptor degradation; rosuvastatin inhibits hepatic HMG-CoA reductase, upregulating LDL receptors — complementary LDL-C lowering

Notes

original target text: PCSK9 (laroprovstat component) + HMG-CoA reductase (rosuvastatin component)

This mechanism combines two complementary strategies for lowering low-density lipoprotein cholesterol (LDL-C), a lipid particle strongly linked to atherosclerotic cardiovascular disease. HMG-CoA reductase is the rate-limiting enzyme in the liver's synthesis of cholesterol; statins inhibit it, which reduces intracellular cholesterol and prompts liver cells to display more LDL receptors on their surface to import cholesterol from the blood. PCSK9 is a protein secreted mainly by the liver that binds these LDL receptors and marks them for degradation, reducing how many receptors are available to clear LDL-C. Statins, by lowering cholesterol synthesis, actually increase PCSK9 production as a compensatory response, which partly limits how much a statin alone can lower LDL-C. Combining a PCSK9 inhibitor with a statin addresses this feedback loop directly: the statin increases LDL receptor expression while the PCSK9 inhibitor prevents those receptors from being degraded, allowing more of them to persist on the liver surface and clear LDL-C from circulation. This dual approach is relevant wherever aggressive LDL-C reduction is medically desired, such as in people with elevated cardiovascular risk or hereditary lipid disorders, and an oral small-molecule PCSK9 inhibitor combined with a statin in one fixed-dose product offers a more convenient way to achieve this pairing than separate injectable and oral therapies.